東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Responsiveness of the Hexoskin Smart...

Mujaddid, Ahzum.

FindBook

Google Book

Amazon

博客來

Responsiveness of the Hexoskin Smart Shirt to Detect Pharmacological Lung Volume Reduction at Rest and During Exercise in People with Copd.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Responsiveness of the Hexoskin Smart Shirt to Detect Pharmacological Lung Volume Reduction at Rest and During Exercise in People with Copd./
作者:	Mujaddid, Ahzum.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2023,
面頁冊數:	79 p.
附註:	Source: Masters Abstracts International, Volume: 85-11.
Contained By:	Masters Abstracts International85-11.
標題:	Exercise. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31079231
ISBN:	9798382618050

Responsiveness of the Hexoskin Smart Shirt to Detect Pharmacological Lung Volume Reduction at Rest and During Exercise in People with Copd.
Mujaddid, Ahzum.

Responsiveness of the Hexoskin Smart Shirt to Detect Pharmacological Lung Volume Reduction at Rest and During Exercise in People with Copd. - Ann Arbor : ProQuest Dissertations & Theses, 2023 - 79 p.

Source: Masters Abstracts International, Volume: 85-11.

Thesis (M.S.)--McGill University (Canada), 2023.

Introduction: The role of wearable biosensor technology for the health monitoring of people with chronic respiratory diseases, like chronic obstructive pulmonary disease (COPD), has increased tremendously in recent years. Though many wearable health monitoring devices are commercially available, very few have been clinically validated nor are they able to measure changes in ventilatory parameters and operating lung volumes, key physiological indicators of lung health and disease progression for people with COPD. In light of this, Hexoskin is a commercially available wearable smart shirt that is unique in its potential to measure changes in ventilatory parameters and operating lung volumes. Objectives: To determine 1) the responsiveness of Hexoskin to measure bronchodilator-induced changes in tidal volume (VT), ventilation (V'E), respiratory rate (RR), inspiratory capacity (IC) and inspiratory reserve volume (IRV) at rest and during exercise in people with COPD compared to a laboratory (gold)-standard respiratory monitoring device, a Vmax Encore Metabolic Cart (Vmax); and 2) the ability of Hexoskin to validly measure VT, V'E, RR, IC, and IRV at rest and during exercise in people with COPD, compared to Vmax. Methods: Ventilatory parameters (VT, V'E, RR) and operating lung volumes (IC, IRV) were simultaneously collected using Hexoskin and Vmax in 6 adults (4 males, 2 females) with COPD (FEV1 % predicted = 53.8% ± 17.7; FEV1/FVC = 0.44 ± 0.13). Participants performed spirometry and a 3-minute constant rate stair stepping test (3-MIN CRSST) before and 60-min after inhalation of nebulized Combivent® (500 mcg/2 mL ipratropium bromide + 2.5 mg/2.5 mL salbutamol), a powerful short-acting bronchodilator. Results: Both Hexoskin and Vmax recorded exercise-induced increases in VT, V'E and RR under both pre- and postbronchodilator conditions, whereas only Vmax documented decreases in IRV from baseline to the end of the 3-MIN CRSST. Neither Hexoskin nor Vmax documented a change in IC from rest during the exercise both before and after inhalation of nebulized Combivent®. Significant correlations were observed between paired Hexoskin and Vmax-derived measures of VT (R2 =0.27, p<0.001) V'E (R2 =0.54, p<0.001), and RR (R2 =0.62, p<0.001) within the pooled data from baseline and exercise under both pre- and post-bronchodilator conditions; however, no such associations were observed between paired Hexoskin and Vmax-derived measures of IC (R2 =0.03, p=0.194), and IRV (R2=0.06, p=0.143). Single-dose inhalation of nebulized Combivent® had no effect on Hexoskin or Vmax-derived measures of V'E, VT, RR, IC and IRV at baseline, during exercise or recovery. There was also no association between bronchodilator-induced changes in Hexoskin and Vmax-derived measures of VT (R2 =0.05, p=0.591), V'E (R2 =0.02, p=0.566), RR (R2 =0.02, p=0.604), IC (R2 =0.02, p=0.454), and IRV (R2 =0.17, p=0.082) within the pooled data from baseline, exercise, and recovery. Conclusion:The preliminary results of this study (i) add to the growing evidence base supporting the use of Hexoskin as a valid remote monitoring device to document changes in ventilation and breathing pattern during daily life activities, like stair climbing, in people with COPD; and (ii) indicate that Hexoskin is neither a valid nor responsive tool to detect changes in operating lung volumes due to exercise and/or bronchodilator therapy in people with COPD.

ISBN: 9798382618050Subjects--Topical Terms:

532868
Exercise.

Responsiveness of the Hexoskin Smart Shirt to Detect Pharmacological Lung Volume Reduction at Rest and During Exercise in People with Copd.
LDR:04486nmm a2200325 4500 001 2404192
005 20241203090557.5
006 m o d
007 cr#unu||||||||
008 251215s2023 ||||||||||||||||| ||eng d
020 $a 9798382618050
035 $a (MiAaPQ)AAI31079231
035 $a (MiAaPQ)McGill_2f75rf40t
035 $a AAI31079231
040 $a MiAaPQ $c MiAaPQ
100 1 $a Mujaddid, Ahzum. $3 3774487
245 1 0 $a Responsiveness of the Hexoskin Smart Shirt to Detect Pharmacological Lung Volume Reduction at Rest and During Exercise in People with Copd.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2023
300 $a 79 p.
500 $a Source: Masters Abstracts International, Volume: 85-11.
500 $a Advisor: Jensen, Dennis.
502 $a Thesis (M.S.)--McGill University (Canada), 2023.
520 $a Introduction: The role of wearable biosensor technology for the health monitoring of people with chronic respiratory diseases, like chronic obstructive pulmonary disease (COPD), has increased tremendously in recent years. Though many wearable health monitoring devices are commercially available, very few have been clinically validated nor are they able to measure changes in ventilatory parameters and operating lung volumes, key physiological indicators of lung health and disease progression for people with COPD. In light of this, Hexoskin is a commercially available wearable smart shirt that is unique in its potential to measure changes in ventilatory parameters and operating lung volumes. Objectives: To determine 1) the responsiveness of Hexoskin to measure bronchodilator-induced changes in tidal volume (VT), ventilation (V'E), respiratory rate (RR), inspiratory capacity (IC) and inspiratory reserve volume (IRV) at rest and during exercise in people with COPD compared to a laboratory (gold)-standard respiratory monitoring device, a Vmax Encore Metabolic Cart (Vmax); and 2) the ability of Hexoskin to validly measure VT, V'E, RR, IC, and IRV at rest and during exercise in people with COPD, compared to Vmax. Methods: Ventilatory parameters (VT, V'E, RR) and operating lung volumes (IC, IRV) were simultaneously collected using Hexoskin and Vmax in 6 adults (4 males, 2 females) with COPD (FEV1 % predicted = 53.8% ± 17.7; FEV1/FVC = 0.44 ± 0.13). Participants performed spirometry and a 3-minute constant rate stair stepping test (3-MIN CRSST) before and 60-min after inhalation of nebulized Combivent® (500 mcg/2 mL ipratropium bromide + 2.5 mg/2.5 mL salbutamol), a powerful short-acting bronchodilator. Results: Both Hexoskin and Vmax recorded exercise-induced increases in VT, V'E and RR under both pre- and postbronchodilator conditions, whereas only Vmax documented decreases in IRV from baseline to the end of the 3-MIN CRSST. Neither Hexoskin nor Vmax documented a change in IC from rest during the exercise both before and after inhalation of nebulized Combivent®. Significant correlations were observed between paired Hexoskin and Vmax-derived measures of VT (R2 =0.27, p<0.001) V'E (R2 =0.54, p<0.001), and RR (R2 =0.62, p<0.001) within the pooled data from baseline and exercise under both pre- and post-bronchodilator conditions; however, no such associations were observed between paired Hexoskin and Vmax-derived measures of IC (R2 =0.03, p=0.194), and IRV (R2=0.06, p=0.143). Single-dose inhalation of nebulized Combivent® had no effect on Hexoskin or Vmax-derived measures of V'E, VT, RR, IC and IRV at baseline, during exercise or recovery. There was also no association between bronchodilator-induced changes in Hexoskin and Vmax-derived measures of VT (R2 =0.05, p=0.591), V'E (R2 =0.02, p=0.566), RR (R2 =0.02, p=0.604), IC (R2 =0.02, p=0.454), and IRV (R2 =0.17, p=0.082) within the pooled data from baseline, exercise, and recovery. Conclusion:The preliminary results of this study (i) add to the growing evidence base supporting the use of Hexoskin as a valid remote monitoring device to document changes in ventilation and breathing pattern during daily life activities, like stair climbing, in people with COPD; and (ii) indicate that Hexoskin is neither a valid nor responsive tool to detect changes in operating lung volumes due to exercise and/or bronchodilator therapy in people with COPD.
590 $a School code: 0781.
650 4 $a Exercise. $3 532868
650 4 $a Respiration. $3 610890
650 4 $a Anticholinergics. $3 3774488
650 4 $a Chronic obstructive pulmonary disease. $3 3558078
650 4 $a Kinesiology. $3 517627
650 4 $a Medicine. $3 641104
690 $a 0575
690 $a 0564
710 2 $a McGill University (Canada). $3 1018122
773 0 $t Masters Abstracts International $g 85-11.
790 $a 0781
791 $a M.S.
792 $a 2023
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31079231